Market Place
Sourcing Support
FDA declines full approval for Intercept`s liver disease drug
13 Nov 2024 //
REUTERS
Intercept Receives CRL from FDA Addressing OCALIVA Snda
12 Nov 2024 //
GLOBENEWSWIRE
Intercept Provides Regulatory Update Regarding sNDA for OCALIVA
17 Oct 2024 //
GLOBENEWSWIRE
Company Statement on FDA Advisory Committee Meeting
14 Sep 2024 //
GLOBENEWSWIRE
FDA Staff Questions Confirmatory Trial Data For Intercept`s Liver Drug
12 Sep 2024 //
ENDPTS
Advanz Pharma Secures Suspension Of EC Decision On OCALIVA
05 Sep 2024 //
GLOBENEWSWIRE
Advanz Pharma Responds to EU Commission`s OCALIVA Revocation for PBC
03 Sep 2024 //
GLOBENEWSWIRE
US FDA grants accelerated approval to Genfit and Ipsen`s liver disease drug
11 Jun 2024 //
REUTERS
Intercept Announces FDA Acceptance of sNDA for Ocaliva
29 Feb 2024 //
GLOBENEWSWIRE
Alfasigma to take over struggling Intercept
27 Sep 2023 //
FIERCE PHARMA
Optimus` Generic Obeticholic Acid Receives Approval in the U.S.
20 Jul 2023 //
FDA
Intercept restructures as NASH hopes dashed again by FDA
23 Jun 2023 //
FIERCE PHARMA
Intercept Receives Complete Response Letter from FDA for Obeticholic Acid
22 Jun 2023 //
GLOBENEWSWIRE
MSN`s Generic Obeticholic Acid Receives Receives Approval in the U.S.
30 May 2023 //
FDA
Apotex`s Generic Obeticholic Acid Receives Receives Approval in the U.S.
30 May 2023 //
FDA
Brain implant maker Paradromics nabs $33M, FDA breakthrough tag
19 May 2023 //
FIERCE BIOTECH
Intercept Announces FDA Advisory Committee Meeting Date for Obeticholic Acid
10 Mar 2023 //
GLOBENEWSWIRE
Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid
23 Dec 2022 //
GLOBENEWSWIRE
New Study Published in The American Journal Pathology Suggests Obeticholic Acid
08 Dec 2022 //
GLOBENEWSWIRE
Improved Transplant-Free Survival Observed with Obeticholic Acid
20 Sep 2022 //
GLOBENEWSWIRE
Intercept Announces Positive Data in Fibrosis from PIII REGENERATE Study of OCA
07 Jul 2022 //
GLOBENEWSWIRE
Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC
05 May 2022 //
GLOBENEWSWIRE
Intercept pulls EU filing for NASH drug obeticholic acid
09 Dec 2021 //
PHARMAPHORUM
Intercept, awaiting needed trial data, pulls its NASH drug application in Europe
09 Dec 2021 //
BIOPHARMADIVE
Intercept Announces New Long-Term Data Demonstrating of Obeticholic Acid
15 Nov 2021 //
YAHOO
Intercept Announces New Long-Term Data of Obeticholic Acid
15 Nov 2021 //
GLOBENEWSWIRE
Received CEP approval for Tranexamic Acid
18 Aug 2021 //
PRESS RELEASE
FDA restricts use of Intercept drug due to liver injury risk
28 May 2021 //
BIOPHARMADIVE
FDA Restricts Obeticholic Acid (Ocaliva) Over Serious Liver Injury Risk
26 May 2021 //
MEDSCAPE
In another blow to Intercept, the FDA is investigating Ocaliva for risk
10 Oct 2020 //
ENDPTS
ICER Publishes Evidence Report on Obeticholic Acid for the of Nonalcoholic
21 Jul 2020 //
REVIEW
Intercept CRL Likely About OCA-Specific Concerns, Not NASH Endpoints
01 Jul 2020 //
PINK
Intercept shares fall as FDA again delays closely watched NASH drug
23 May 2020 //
BIOPHARMADIVE
Dr Reddy’s Labs launches generic Ocaliva in India
21 May 2020 //
PHARMABIZ
Intercept`s closely watched NASH drug hits a COVID-19 snag
28 Mar 2020 //
FIERCE PHARMA
2 NASH drugmakers have wildly different Mondays
25 Nov 2019 //
BIOPHARMADIVE
Noninvasive tests can advance NASH diagnostics: analysis
12 Nov 2019 //
FIERCE PHARMA
Genfit goes to China with a deal worth up to $228M for NASH drug
24 Jun 2019 //
ENDPTS
NGM backs up case for once-monthly dosing of Merck-partnered NASH drug
11 Jun 2019 //
FIERCE BIOTECH
Safety concerns over NASH hopeful Ocaliva `overblown`: analyst
12 Apr 2019 //
FIERCE PHARMA
Safety concerns over NASH hopeful Ocaliva `overblown`: analyst
12 Apr 2019 //
FIERCE PHARMA
While we wait for NASH data, Genfit reports pos elafibranor data
06 Dec 2018 //
ENDPTS
Intercept Pharma Notches 2 Upgrades On Ocaliva Prospects
06 Aug 2018 //
BENGINGA
Liver Biopsy Data from POISE Ph3 Substudy Supports Obeticholic Acid’s Ability
13 Apr 2018 //
PRESS RELEASE
Intercept Announces Multiple New Ocaliva® (obeticholic acid) Data Presentation
23 Mar 2018 //
PRESS RELEASE
Intercept Announces Updated U.S. Prescribing Information for Ocaliva®
01 Feb 2018 //
PRESS RELEASE
Novartis has assets to sell, investors wary of what it might buy
30 May 2017 //
TIMES OF INDIA
Minister Naledi Pandor On Agreement Boosting CTRL & Research Capability
29 May 2017 //
ALLAFRICA
Ocalvia gets NHS green light for rare chronic liver disease
28 Apr 2017 //
PHARMA TIMES
NICE backs new treatment for chronic liver disease
04 Mar 2017 //
PHARMA TIMES
Why Intercept Pharma Stock Jumped Nearly 10% On Friday
10 Feb 2017 //
BIOSPACE
Novartis AG Rumored to Be Buying Intercept Pharma
30 Dec 2016 //
BIOSPACE
European Commission Grants Intercept’s Ocaliva Marketing Authorization
15 Dec 2016 //
GLOBENEWSWIRE
3 Potential Acquisition Targets for Gilead Sciences, Inc.
16 Nov 2016 //
THE MOTLEY FOOL
Eight Medicines win CHMP Nod
18 Oct 2016 //
PHARMATIMES
Intercept’s Ocaliva Gains PBC Thumbs in Europe, but with Caveats
15 Oct 2016 //
FIERCE BIOTECH
